Cellectis S.A. ALCLS

European equities traded in the US as American depositary receipts were trending lower late Wednesda

European equities traded in the US as American depositary receipts were tracking slightly lower Thur

European equities traded in the US as American depositary receipts were tracking lower Wednesday mor

European equities traded in the US as American depositary receipts Tuesday were tracking lower Tuesd

European equities traded in the US as American depositary receipts started the week higher on Monday

European equities traded in the US as American depositary receipts were heading lower late Friday mo

European equities traded in the US as American depositary receipts were rising sharply late Thursday

Cellectis S.A. (NASDAQ:CLLS) announced on September 14 that its board approved a strategic transformation on September 11. It will exit internal development of lasme-cel and eti-cel, seek partners for those cancer therapies, and prioritize two preclinical programs for severe lipid disorders. The shift moves the internal pipeline toward in vivo treatment, delivering editing machinery directly […]

European equities traded in the US as American depositary receipts edged higher late Wednesday morni

Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy

European equities traded in the US as American depositary receipts opened the week tracking sharply

Cellectis is shifting its development strategy toward in vivo gene editing after reporting preclinical proof-of-concept for. HEAL-101 and.

Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.

Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by continuing existing cell therapy partnerships while exiting lasme-cel and eti-cel developmentRealignment of the operating model targeting Cellectis cash runway extension into H2 2028Conference call and webcast on September 14: English at 8 a.m. ET, French at 9 a.m. ET NEW YORK, Sept. 14, 2026 (GLOBE NE

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update. Conference Call and Webcast Details: September 14, 2026 English-language at 8:00 a.m. ET. / 2:00 p.m. CET Webcast link:https://viavid.

European equities traded in the US as American depositary receipts were trending higher late Friday

European equities traded in the US as American depositary receipts were trending lower late Thursday